NCT02213705View on ClinicalTrials.gov

Treatment of Refractory Sever Systemic Scleroderma by Injection of Allogeneic Mesenchymal Stem Cells

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

May 6, 2014

Primary Completion Date

February 9, 2020

Study Completion Date

June 16, 2022

Conditions
SYSTEMIC SCLERODERMAALLOGENEIC MESENCHYMAL STEM CELLSADULT
Interventions
BIOLOGICAL

INJECTION OF ALLOGENEIC MESENCHYMAL STEM CELLS

Trial Locations (1)

75010

Saint-Louis Hospital, Paris

All Listed Sponsors
lead

Assistance Publique - Hôpitaux de Paris

OTHER

NCT02213705 - Treatment of Refractory Sever Systemic Scleroderma by Injection of Allogeneic Mesenchymal Stem Cells | Biotech Hunter | Biotech Hunter